Florida Sued Drugmakers Over Diabetes Drug Pricing
The state alleges that manufacturers and pharmacy benefit managers engaged in deceptive, anti-competitive pricing practices.
Updated on Sept. 22, 2026 in Diabetes
Live Poll
Should major pharmaceutical manufacturers and pharmacy benefit managers face more legal action over drug prices?
Florida Attorney General James Uthmeier has filed a lawsuit against major insulin manufacturers and pharmacy benefit managers (PBMs) for alleged price-fixing. The legal action impacts the 2.3 million Florida adults currently managing a diabetes diagnosis.
Why it matters
The suit addresses concerns over the affordability and access of essential diabetes medications by challenging the business practices of companies that dominate the insulin market. Residents may see future implications for how their prescriptions are managed and priced.
The lawsuit alleges that manufacturers and PBMs utilized rebate aggregators to inflate costs, impacting a population of 2.3 million Florida adults with diagnosed diabetes. The litigation highlights potential anti-competitive behavior in a market dominated by a small group of firms.
The players
James Uthmeier
The Florida Attorney General leading the legal action against pharmaceutical companies and pharmacy benefit managers.
Eli Lilly, Novo Nordisk, and Sanofi
Major pharmaceutical manufacturers that collectively supply more than 90% of the world's insulin.
CVS Caremark, Express Scripts, and Optum Rx
Pharmacy benefit managers responsible for processing approximately 80% of prescriptions in the United States.
The details
The state alleges that the defendants, including Eli Lilly, Novo Nordisk, and Sanofi, coordinated with PBMs like CVS Caremark, Express Scripts, and Optum Rx to manipulate drug pricing. These entities reportedly used rebate aggregators—intermediaries such as Zinc, Ascent, and Emisar—to manage and obscure the actual costs of insulin and other diabetes treatments. The attorney general claims these coordinated efforts constitute price-fixing and deceptive trade practices under state law.
Timeline
Tuesday, September 22, 2026: Lawsuit announced at a news conference in Tampa, Florida.
Health Landscape
This lawsuit utilizes the Florida Deceptive and Unfair Trade Practices Act to challenge the consolidated structure of the modern pharmaceutical supply chain. It follows a growing trend of state-level oversight aimed at curbing the influence of pharmacy benefit managers on drug affordability.
While this legal action is ongoing, it does not change your current prescriptions or insurance coverage. If you are concerned about the cost of your diabetes medication, discuss options for generic alternatives or patient assistance programs with your doctor.
The takeaway
This lawsuit highlights the ongoing scrutiny of pricing transparency within the insulin supply chain. Patients are encouraged to track their out-of-pocket medication costs and consult their physician or pharmacist to discuss potential cost-saving strategies.
What happens next
The Florida Attorney General has indicated that additional lawsuits regarding drug pricing are expected to be filed in the coming weeks and months.
Further reading
Learn more about the latest news regarding Diabetes management and access.
Live Poll
Should major pharmaceutical manufacturers and pharmacy benefit managers face more legal action over drug prices?
